# Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124

Study · id `cardio:ct-nct05459688` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05459688](<https://clinicaltrials.gov/study/NCT05459688>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05459688

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 175 participants.

## Technical summary

Registry record NCT05459688. Allocation not applicable; no masking; primary purpose treatment. Start 2022-04-06 (actual); primary completion 2023-11-07 (actual). Results posted on 2024-12-16.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 175 participants (enrolled count; ClinicalTrials.gov record NCT05459688, source copy `cardio:ctgov-nct05459688-2024-12-16`, retrieved 2026-10-26)
- Started: 2022-04-06 (actual) (ClinicalTrials.gov record NCT05459688, source copy `cardio:ctgov-nct05459688-2024-12-16`, retrieved 2026-10-26)
- Primary completion: 2023-11-07 (actual) (ClinicalTrials.gov record NCT05459688, source copy `cardio:ctgov-nct05459688-2024-12-16`, retrieved 2026-10-26)
- Completion: 2023-11-07 (actual) (ClinicalTrials.gov record NCT05459688, source copy `cardio:ctgov-nct05459688-2024-12-16`, retrieved 2026-10-26)
- Results first posted: 2024-12-16 (ClinicalTrials.gov record NCT05459688, source copy `cardio:ctgov-nct05459688-2024-12-16`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05459688, source copy `cardio:ctgov-nct05459688-2024-12-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05459688-2024-12-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124
- Condition: Hypertension
- Intervention (Drug): CIN-107
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 9e9c801b9194d872b42b411104edb7b45f56a2c99a60a1fd8ee6a268ea044946
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
